Adaptimmune Reports Second Quarter 2017 Financial Results

– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –

       – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications –

– On track for initial data from our wholly-owned assets in 2017 and 2018 –

            – NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) continue to indicate a favorable risk benefit profile in synovial sarcoma –

PHILADELPHIA and OXFORD, U.K., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended June 30, 2017.

“This was a very exciting quarter for Adaptimmune,” commented James Noble, Adaptimmune’s Chief Executive Officer. “We made significant progress clinically by initiating our first trials with two proprietary programs, MAGE-A4 and AFP, and also initiated our first combination study with NY‑ESO. We presented data in an oral presentation at ASCO, showing responses in all four cohorts in our NY-ESO synovial sarcoma study. And, importantly, we also extended our cash runway to late 2019, well past the expected data points on all three of our proprietary programs. We are now focused on delivering clinical data across multiple tumor types as we move through the second half of this year and into 2018. We are also very encouraged by FDA’s Oncology Drug Advisory Committee’s recent unanimous endorsement of Novartis’s anti-CD19 CAR-T therapy, with which we share common manufacturing process elements, as this is a positive review of the first gene therapy cell product in the US.”

Recent Corporate Highlights:

  • Completed April 2017 registered direct offering to Matrix Capital Management Company, LP, which combined with March 2017 public offering, raised total net proceeds of $103.2 million; 
  • Initiated AFP SPEAR T-cell therapy clinical trial in hepatocellular carcinoma;
  • Initiated MAGE-A4 SPEAR T-cell therapy clinical trial in urothelial (bladder), melanoma, head & neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers;
  • Initiated clinical trial of NY-ESO SPEAR T‑cells in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma;
  • Presented data during an oral presentation at ASCO from ongoing study of NY-ESO SPEAR T-cells in synovial sarcoma indicating that:
    • Initial anti-tumor activity observed in all ongoing cohorts including low expressors of NY‑ESO
    • Fludarabine appears to be an important component of the lymphodepletion regimen
    • NY-ESO continues to be generally well-tolerated:
      • All reported events of cytokine release syndrome resolved, and the majority of events were Grade 1 or 2
      • There were no reported events of seizure, cerebral edema, or encephalopathy
    • Survival and response data in Cohort 1 (non-modified fludarabine / cyclophosphamide [“Flu/Cy”] lymphodepletion regimen) continue to be promising (data cutoff March 30, 2017):
      • Of the 12 patients treated, 5 remain alive with a median predicted overall survival of 120 weeks (~28 months), and 6 responses were observed
      • 10 patients received the target dose of 1 billion transduced NY‑ESO SPEAR T-cells, and the median predicted overall survival for those patients is 159 weeks (~37 months)

Financial Results for the Three Months ended June 30, 2017

  • Cash / liquidity position: As of June 30, 2017, Adaptimmune had cash and cash equivalents of $122.0 million and Total Liquidity1 of $220.0 million.
  • Revenue: Revenue represents the upfront and milestone payments, which are recognized over the period the Company delivers services to GSK. Revenue for the three months ended June 30, 2017 was $3.5 million. The increase in revenue is due to the revenue in the three months ended June 30, 2016 being adversely impacted by a change in estimate of the period over which revenue is being recognized, which reduced revenue in that quarter by $2.8 million.
  • Research and development (“R&D”) expenses: R&D expenses for the three months ended June 30, 2017 were $19.6 million, compared to $16.9 million for the same period of 2016. The increase was primarily due to increased costs associated with clinical trials; costs of developing manufacturing capability in the Company’s U.S. facility and increased personnel expenses.
  • General and administrative (“G&A”) expenses: G&A expenses for the three months ended June 30, 2017 were $7.7 million, compared to $6.2 million for the same period of 2016. The increase was primarily due to increased personnel costs consistent with our planned growth.
  • Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three months ended June 30, 2017 was $20.2 million ($(0.04) per ordinary share or $(0.24) per American Depositary Share (“ADS”) compared to $22.1 million ($(0.05) per ordinary share or $(0.31) per ADS) in the same period of 2016.

Financial Guidance
The Company believes that its existing cash and cash equivalents, short-term deposits and marketable securities will fund the Company’s current operating plan through to late 2019.

1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.

Conference Call Information
The Company will not be holding a conference call this quarter.

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. 

Total Liquidity (a non-GAAP financial measure)
Total Liquidity is the total of cash and cash equivalents, short-term deposits and marketable securities. Each of these components appears in the Consolidated Balance Sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the Consolidated Financial Statements, which reconciles to Total Liquidity as follows:

(in thousands)
  June 30,
    December 31,
Cash and cash equivalents       $   121,998   $   158,779
Short-term deposits     18,000       22,694
Marketable securities     80,023       - 
Total Liquidity $   220,021   $   181,473

The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its management of overall liquidity, financial flexibility, capital structure and leverage.

Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data) 
  Three months ended June 30,   Six months ended June 30,
  2017     2016     2017     2016  
Revenue $ 3,521     $ 328     $ 6,378     $ 3,246  
Operating expenses                      
Research and development(1)    (19,591 )      (16,856 )      (38,206 )      (31,332 )
General and administrative(1)    (7,710 )      (6,172 )      (14,173 )      (11,439 )
Total operating expenses    (27,301 )      (23,028 )      (52,379 )      (42,771 )
Operating loss    (23,780 )      (22,700 )      (46,001 )      (39,525 )
Interest income     512       291       752       550  
Interest expense    (6 )       -         (6 )       -   
Other income, net   3,224       607       3,654       1,656  
Loss before income taxes    (20,050 )      (21,802 )      (41,601 )      (37,319 )
Income taxes    (165 )      (293 )      (396 )      (352 )
Net loss attributable to ordinary shareholders $  (20,215 )   $  (22,095 )   $  (41,997 )   $  (37,671 )
Net loss per ordinary share basic and diluted $  (0.04 )   $  (0.05 )   $  (0.09 )   $  (0.09 )
Weighted average shares outstanding, basic and diluted(2)        





(1) Certain costs have been reclassified in prior periods to conform to the current period presentation.  The net effect is to reduce G&A and increase R&D by $637,000 and $1,225,000 in the three and six months ended June 30, 2016, respectively.

(2) The effect of 67,082,914 and 46,127,274 share options, which are potentially dilutive equity instruments, have been excluded from the diluted loss per share calculation for the three months ended June 30, 2017 and 2016, respectively, because they would have an antidilutive effect on the loss per share for the period.

Condensed Consolidated Balance Sheets
(unaudited, in thousands)
June 30, 2017   December 31, 2016
Current assets          
Cash and cash equivalents 121,998     158,779  
Short-term deposits   18,000       22,694  
Marketable securities - available for sale debt securities   80,023                 -   
Accounts receivable, net of allowance for doubtful accounts of $- and $-   1,406       1,480  
Other current assets and prepaid expenses (including current portion of clinical materials)   16,317       15,798  
Total current assets   237,744       198,751  
Restricted cash   4,156       4,017  
Clinical materials   2,026       2,580  
Property, plant and equipment, net   38,922       27,899  
Intangibles, net   1,431       1,268  
Total assets   284,279       234,515  
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable   4,577       11,350  
Accrued expenses and other accrued liabilities   13,372       17,528  
Deferred revenue   12,304       11,392  
Total current liabilities   30,253       40,270  
Deferred revenue, non-current   20,754       24,962  
Other liabilities, non-current   3,777       3,141  
Total liabilities   54,784       68,373  
Stockholders’ equity          
Common stock - Ordinary shares par value £0.001, 703,103,126 authorized and 561,103,126 issued and outstanding (2016: 574,711,900 authorized and 424,775,092 issued and outstanding)     853         683  
Additional paid in capital   448,985       341,200  
Accumulated other comprehensive loss    (16,854 )      (14,249 )
Accumulated deficit    (203,489 )      (161,492 )
Total stockholders’ equity   229,495       166,142  
Total liabilities and stockholders’ equity $ 284,279     $ 234,515  

Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
 Six months ended
June 30,
  2017     2016  
Cash flows from operating activities          
Net loss $   (41,997 )   $   (37,671 )
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation     2,023         1,512  
Amortization     159         82  
Share-based compensation expense     4,757         4,541  
Loss on disposal of property, plant and equipment     194         -   
Unrealized foreign exchange gains     (3,206 )       (2,004 )
Changes in operating assets and liabilities:          
Increase in receivables and other operating assets     2,301         601  
(Increase) decrease in non-current operating assets     (554 )       2,041  
Decrease in payables and deferred revenue     (10,125 )       (4,274 )
Net cash used in operating activities     (46,448 )       (35,172 )
Cash flows from investing activities          
Acquisition of property, plant and equipment     (21,188 )       (2,910 )
Acquisition of intangibles     (266 )       (861 )
Proceeds from disposal of property, plant and equipment     550         -   
Maturity of short-term deposits   22,857         41,661  
Investment in short-term deposits   (18,000 )       (42,837 )
Investment in marketable securities     (79,774 )       -   
Net cash used in investing activities     (95,821 )       (4,947 )
Cash flows from financing activities          
Proceeds from issuance of common stock, after offering expenses of $4,774     103,167         -   
Proceeds from exercise of stock options   31         -   
Net cash provided by financing activities     103,198         -   
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash     2,290         (3,529 )
Net decrease in cash and cash equivalents    (36,642 )      (43,648 )
Cash, cash equivalents and restricted cash at start of period     162,796         198,771  
Cash, cash equivalents and restricted cash at end of period $   126,154     $   155,123  
Adaptimmune Contacts

Investor Relations
Juli P. Miller, Ph.D.
T: (215) 825-9310

Media Relations
Margaret Henry
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249

Primary Logo

Source: Adaptimmune Therapeutics plc